SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
TNXP

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$2.38-$0.17 (-6.67%)
 
Market cap
$46.2M
Insider Score
Analyst consensus
Listed since
May 10, 2012
Market Cap$46.25M-85.2%
Revenue (ttm)n/a+318.0%
Net Incomen/a-82.4%
EPSn/a+37.5%
Shares Out19.43M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,258,986
Open$2.58
Previous Close$2.55
Day's Range$2.31 - $2.60
52-Week Range$2.30 - $20.56
Beta1.90
AnalystsBuy
Price Target$22.50(+845.38%)
Earnings Daten/a

About TNXP

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.

Address
200 Connell Drive, Berkeley Heights, NJ, 07928, US
Market Cap
46 million
Employees
142
Industrial Classification
Biotechnology

Tonix Pharmaceuticals Holding Corp. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
9th Percentile Overall Score
TNXP InsiderScore:47 / 99

Tonix Pharmaceuticals Holding Corp. scored higher than 9% of companies evaluated by InsiderBuying, and ranked 80th out of 107 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Tonix Pharmaceuticals Holding Corp. bought $47.9K of stock across 2 purchases in the last 90 days, the largest of them $27.6K.

Stake Increase

The average purchase added about 42% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$479.03K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
-6.67%
5 Days
-21.19%
1 Month
-56.17%
6 Months
-83.00%
1 Year
-85.22%

$TNXP stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in TNXP holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by TNXP's directors and management

Net Shares Purchased by Insiders−20k−10k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

TNXP Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New TNXP patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to TNXP from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in TNXP

VTIVanguard Morningstar Total Stock Market ETF$1.96M
IWMiShares Russell 2000 ETF$1.08M
VXFVanguard Extended Market ETF$955.81K
FESMFidelity Enhanced Small Cap ETF$541.63K
VTWOVanguard Russell 2000 ETF$490.31K
IWNiShares Russell 2000 Value ETF$402.25K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from TNXP’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
46.48
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Strong Tonmya revenue growth (37% QoQ) and expanding insurance coverage offset analyst concerns about valuation and funding risks.

Recent Insider Activity

Buys
8
Sells
0
Buy Value
$479.03K
Distinct Buyers
4

Insider Score Trend Over Time

+11.5 since Sep 23
0255075100Sep 23 — Insider Score 34.9Sep 24 — Insider Score 34.1Sep 25 — Insider Score 49.0Sep 26 — Insider Score 48.9Sep 27 — Insider Score 49.0Sep 28 — Insider Score 49.2Sep 29 — Insider Score 48.6Sep 30 — Insider Score 48.4Oct 1 — Insider Score 47.7Oct 2 — Insider Score 45.0Oct 3 — Insider Score 47.6Oct 4 — Insider Score 47.6Oct 5 — Insider Score 47.7Oct 6 — Insider Score 46.9Oct 7 — Insider Score 46.5Oct 8 — Insider Score 46.4Oct 9 — Insider Score 46.0Oct 10 — Insider Score 45.5Oct 11 — Insider Score 46.5Oct 12 — Insider Score 46.5Oct 13 — Insider Score 46.9Oct 14 — Insider Score 46.5Oct 15 — Insider Score 46.5Oct 16 — Insider Score 46.0Oct 17 — Insider Score 46.0Oct 18 — Insider Score 46.3Oct 19 — Insider Score 46.0Oct 20 — Insider Score 46.0Oct 21 — Insider Score 45.8Oct 22 — Insider Score 45.8Oct 23 — Insider Score 45.8Oct 24 — Insider Score 45.8Oct 25 — Insider Score 45.5Oct 26 — Insider Score 45.3Oct 27 — Insider Score 45.4Oct 28 — Insider Score 45.3Oct 29 — Insider Score 44.6Oct 30 — Insider Score 43.7Oct 31 — Insider Score 43.2Nov 1 — Insider Score 43.4Nov 2 — Insider Score 43.4Nov 3 — Insider Score 42.5Nov 4 — Insider Score 41.8Nov 5 — Insider Score 41.0Nov 6 — Insider Score 40.1Nov 7 — Insider Score 39.5Nov 8 — Insider Score 40.2Nov 9 — Insider Score 40.6Nov 10 — Insider Score 39.0Nov 11 — Insider Score 38.0Nov 12 — Insider Score 57.9Nov 13 — Insider Score 57.1Nov 14 — Insider Score 56.3Nov 15 — Insider Score 56.5Nov 16 — Insider Score 56.2Nov 17 — Insider Score 54.6Nov 18 — Insider Score 49.5Nov 19 — Insider Score 48.2Nov 20 — Insider Score 47.4Nov 21 — Insider Score 46.5Sep 23Oct 22Nov 21

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

QQQSInvesco NASDAQ Future Gen 200 ETF0.15%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.05%
IBRNiShares Neuroscience and Healthcare ETF0.04%
FSEVFidelity Enhanced Small Cap Value ETF0.02%

Weight is the stock’s share of each fund’s holdings.